EMA Recommends New Medicines, Orphan Treatment for Rett Syndrome, and Influenza Vaccine, While Advising Revocation of Tavneos Authorization

The European Medicines Agency (EMA) has issued several recommendations, including granting marketing authorization for three new medicines and an orphan treatment for rare Rett Syndrome. Additionally, the EMA recommended approval for Aujemflu, an influenza vaccine for individuals aged 50 and older. Conversely, the Committee for Medicinal Products for Human Use (CHMP) advised revoking the market authorization for Tavneos (avacopan), a drug for inflammatory blood vessel conditions, citing incorrect and misleading data from its pivotal 'Advocate' study.